Androgen receptors frequently are expressed in breast carcinomas (original) (raw)
Background. To our knowledge, the hormone receptor status of noncontiguous ductal carcinoma in situ (DCIS) occurring concurrently in ER/PgR-negative invasive cancer has not been studied. The current study was undertaken to investigate the ER/PgR receptor status of DCIS of the breast in patients with ER/PgR-negative invasive breast cancer. Methods. We reviewed the immunohistochemical (IHC) staining for ER and PgR of 187 consecutive cases of ER/PgR-negative invasive breast cancers, collected from 1995 to 2002. To meet the criteria for the study, we evaluated ER/PgR expression of DCIS cancer outside of the invasive breast cancer. Results. A total of 37 cases of DCIS meeting the above criteria were identified. Of these, 16 cases (43.2%) showed positive staining for ER, PgR, or both. Conclusions. In our study of ER/PgR-negative invasive breast cancer we found that in 8% of cases noncontiguous ER/PR-positive DCIS was present. In light of this finding, it may be important for pathologists to evaluate the ER/PgR status of DCIS occurring in the presence of ER/PgR-negative invasive cancer, as this subgroup could be considered for chemoprevention.
Turkish Journal of Pathology, 2016
iNTRoDuCTioN estrogen (eR) and progesterone receptors (PR) are considered to be predictive markers for the patient response to hormonal therapy in breast cancer (1). In addition to its prognostic value, human epidermal growth factor receptor (heR2) is an important predictive marker to predict the patient's response to Trastuzumab in mammary carcinomas. Trastuzumab is a humanized monoclonal antibody used, in combination with other drugs, in the treatment of heR2 positive breast carcinomas (2, 3). The american Society of Clinical Oncology (aSCO) and the College of american Pathologists (CaP) outlined guidelines for testing of heR2, eR and PR with continuous review and updates (1, 4, 5). Currently these guidelines require heR2 testing on metastatic and recurrent breast carcinomas (6, 7). It has been published that approximately 20% of breast cancers are heR2 positive for gene amplification or show protein overexpression by immunohistochemistry (IhC) (8, 9). Therefore, determination of heR2 status is critical for patient care and for prediction of response to Trastuzumab. IhC and Fluorescence in situ hybridization (FISh) are the most commonly used methods for testing the heR2 status (5). FISh analysis may be considered by some superior to that of IhC in predicting response to trastuzumab in patients with mammary carcinoma. This may be related to the strict criteria used as cut off in FISh analysis compared to the subjective analysis with personal variations in evaluating IhC results (10). however, others have reported that IhC is as effective as FISh in predicting the response to treatment (11). The concordance has been found to be high among IhC and FISh in negative (0 and 1+) and positive (3+) cases. Steroid hormone receptors (eR and PR) are prognostic markers that determine to great extent the response to adjuvant hormonal therapy. It is the standard of care to test eR and PR in all cases of invasive breast carcinomas and to test eR in ductal carcinoma in situ (DCIS) (5, 12).
Evaluation of Hormone Receptors Status in Breast Carcinoma
Journal of Shaheed Suhrawardy Medical College, 2019
Background & objective: The importance of establishing hormone receptor status of tumors for the treatment of women with hormone receptor-positive breast cancer is often emphasized. It is critical to evaluate hormone receptor status when considering response to endocrine therapy. The present study was intended to evaluate the usefulness of hormone receptor status in breast carcinoma. Materials & Methods: The present study was conducted in the Department of Pathology, Dhaka Medical College, Dhaka over a period 12 months from July 2009 to June 2010. A total of 30 histopathologically diagnosed cases of breast tumors who were also subjected to immunohistochemical (IHC) test for ER, PR status and HER-2/neu were consecutively included in the study. Patients who have already been treated for malignancy or who had a history of receiving radiotherapy were excluded. Result: Age distributions shows that 40% of the patients were early middle-aged (30-40 years), 30% middle-aged and the rest were either < 30 years or >50 years old. Left breast was involved more often (56.7%) than the right breast (43.3%). The predominant location was upper outer quadrant (43.3%), followed by upper inner quadrant (20%), lower outer quadrant (20%), lower inner quadrant (10%) and central (6.7%). Over half (53.3%) of the tumors were < 5 cm and the rest 5 cm or more. Nearly half (46.7%) of the tumors were moderately differentiated, 36.6% well-differentiated and 16.7% poorly differentiated. In majority (83.3%) of the cases lymph-nodes (axillary lymph nodes) were involved. Based on estrogen and progesterone receptor status, over half (53.3%) of the tumors were ER and PR positive and 40% were Her2/neu overexpressed. Conclusion: The study concluded that half of the Bangladeshi breast cancer patients are ER and PR positive and two in every five cases are Her2/neu overexpressed.
Folia Histochemica et Cytobiologica, 2009
Contents of estrogen receptors (ER) and progesterone receptors (PgR) in cells of breast cancers represent strong predictive factors. The higher is the contents of ER and PgR in breast cancer, the higher is a probability of obtaining a response to hormonal therapy and prognosis for the patient is better. In a routine manner, all tumours of mammary gland are subjected to evaluation of ER and PgR expression using immunohistochemistry. Forty ductal breast cancers (pT 2 N 0 ) were subjected to an immunohistochemical evaluation (IHC) aimed at detection of ER and PgR expression. From every tumour three samples were taken for immunohistochemical studies: the lateral one from the side of axilla (ER-1; PgR-1); the median one (ER-2; PgR-2) and the medial one from the side of sternum (ER-3; PgR-3). The levels of both ER and PgR expression proved to be highly differentiated between the medial zone of the tumour and its periphery. The distinct expression of ER and PgR in ductal breast cancers, dependent on evaluated zone of the tumour, confirms its heterogenous character and exerts an effect on the type of applied treatment.
A Multifactorial Analysis of Steroid Hormone Receptors in Stages I and II Breast Cancer
Annals of Surgery, 1985
It has been shown that the level of estrogen receptors (ER), and to some extent progesterone receptors (PR), correlate to a high degree to the response to endocrine therapy in advanced breast cancer patients. To evaluate the prognostic value of ER/ PR in early breast cancer, 80 patients with stages I and II were studied. They all underwent modified radical mastectomy. Patients with stage I disease (negative LN) received no further treatment, while those with stage II received standard adjuvant chemotherapy. All the patients were followed for 4 years. The ER and PR were measured in each primary tumor by the glycerol density gradient method. Values of 10 fmole/mgm protein or greater were considered positive (+) and less than 10 fmole/mgm were considered negative (-). The results revealed: (1) Fifty-two patients (65%) had ER+, of which 44 (85%) were also PR+; 28 patients had ER-, of which 24 were also PR-(p < 0.0001). (2) ER/PR correlated with age as 71% of the patients over age 50 had ER+/PR+, compared to 33% of those under age 50 (p < 0.05). (3) Postmenopausal patients had a higher incidence of ER+/PR+. (4) Primary tumors less than 2 cm in size had higher ER+; 71% in those with stage I and 80% in stage II. (5) Fifty-eight per cent (38) of patients with ductal carcinoma had ER+/PR+, compared to 67% (4) with lobular carcinoma. (6) The disease-free survival of patients with ER+ tumors was significantly longer than those with ERtumors (p < 0.005) both in positive and negative LN patients. The same was true for PR+ compared to PR-(p < 0.005), but only in those with stage II disease. The overall survival rates were similarly significant in favor of ER+ and PR+ patients (p <0.025), but only in stage II disease. It seems that the status of steroid hormone receptors has a major prognostic factor second only to the LN status. E STROGEN RECEPTORS (ER) have been shown to correlate to a high degree with response to endocrine therapy in breast cancer.' Its determination is now done routinely on all surgically removed breast cancers. If a patient has a negative tumor ER value, the tumor regression in response to endocrine therapy is minimal. If the tumor ER value is positive, there is an increased chance for the tumor to respond to endocrine therapy.2
Współczesna Onkologia, 2015
Aim of the study: Expression of oestrogen and progesterone receptors is a very powerful and useful predictor. Because the response rate to hormonal treatment in breast cancer is associated with the presence of oestrogen and progesterone receptors, assessment of the receptor expression profile allows for prediction of breast cancer response to hormonal treatment. The aim of this study was to assess whether the expression of receptors for oestrogen (ER) and progesterone (PR) in the tumour tissue of patients with invasive breast cancer correlated with tumour histological type, histological grade of malignancy, tumour size, and lymph node status. Material and methods: Materials consisted of histological preparations derived from patients treated for invasive breast cancer. Evaluations were conducted with histopathological and immunohistochemical methods using suitable antibodies. Results: Among 231 cases of breast cancer 18 invasive lobular carcinomas (ILC) and 213 invasive ductal carcinomas (IDC) were diagnosed. Taking the histological type of tumour into account, oestrogen receptor-positive reaction was observed in 74.2% of IDC and 77.8% of ILC, and the positive response to PR was observed in 67.1% of IDC and 61.1% of ILC. Considering the histological grade, ER-in the largest percentage (72%) was observed in second-grade (G2) invasive carcinomas. Similarly, PR expression (75%) was found in the largest percentage in second-grade (G2) carcinomas. Based on our own studies and data from literature, it appears that the ER (+) status is an indicator of good prognosis, because it points to a less aggressive cancer, in which overall survival and disease-free time is longer in comparison with ER (-) tumours. Conclusions: Determination of ER status may, therefore, have significant clinical value and is widely used in routine pathological diagnostics.
Evaluation of estrogen and progesterone receptors in breast cancer
Background and objectives: Previous studies and biological mechanisms of carcinogenesis suggest that the steroid receptors content of breast epithelium may be related to breast cancer risk. The objective in this study was to determine the levels of estrogen receptor (ER) and progesterone receptor (PR) in neoplastic breast epithelium in breast cancer cases. Methods: Between May 2007 and May 2008 at private lab & hospitals (Zheen Hospital), (40) women and one man who were scheduled for diagnostic excisional biopsies of the breast to allow analysis of routinely resected tissue. Histological slides with neoplastic epithelium were available for the 41 cancer cases and neoplastic epithelium was examined with immunohistochemical assays to determine the status of epithelial cells staining for ER and PR. Results: The ER content of neoplastic tissue was higher in the left breast and within young age group cases. The PR content of neoplastic tissue was far lower in both side breast cancer cases but still left side breast cancer cases showing higher progesterone receptors. The relation between ER and PR contents of neoplastic tissue was observed. Conclusion: The results of this study are consistent with the indication of increased ER levels in neoplastic tissue in left breast cancer cases and progesterone receptor is also higher in left side breast cancers. This study contributes to the understanding of breast cancer by examining both ER and PR in neoplastic tissue.
The International journal of biological markers, 2015
Ductal carcinoma in situ (DCIS) is a heterogeneous disease that has not been investigated as widely as invasive breast cancer. Thus, the search for biomarkers capable of identifying DCIS lesions that may recur or progress to invasive cancer is ongoing. Although conventional steroid hormone receptors, cell proliferation and other important tumor markers have been extensively studied in invasive tumors, little is known about the role played by androgen receptors (ARs), widely expressed in breast cancer, in DCIS. We performed a retrospective study in a series of 43 DCIS patients treated with quadrantectomy only and followed up for a period ranging from 5 to 13 years, to evaluate the prognostic relevance of conventional biomarkers (estrogen receptor [ER], progesterone receptor [PgR], Ki67, human epidermal growth factor receptor 2 [HER2]) and AR. Our findings showed that AR and ER were not independent prognostic variables and that an AR/ER ratio cutoff of 1.13 showed a sensitivity of 75%...
JPMA. The Journal of the Pakistan Medical Association, 2009
To determine whether receptor status and HER-2/neu status remains same in primary and metastatic breast carcinoma to corresponding lymph nodes of individual patients. Estrogen receptors, progesterone receptors and HER-2/neu immunohistochemical stains were performed on primary and metastatic breast carcinoma to axillary lymph nodes in 100 patients. Data was collected on a Performa and age, tumour size, type, grade and expression of ER, PR and HER-2/neu on primary and metastatic tumours were recorded. Hormone receptor status was compared between primary and metastatic tumours. Estrogen receptor positivity was observed in 28% primary tumours which were reduced to 25% in metastatic carcinoma. Progesterone receptors were positive in 28% primary tumours as compared to 22% in metastatic tumours. Her-2/neu protein over expression was noted in 44% primary and 45% metastatic breast tumours respectively. In case to case comparison ER, PR and HER-2/neu showed 91%, 88% and 95% concordance in pri...